Abstract. Cannabinoid receptor-1 (CB 1 ) represents a potential drug target against conditions that include obesity and substance abuse. However, drug trials targeting CB 1 (encoded by the CNR1 gene) have been compromised by differences in patient response. Towards addressing the hypothesis that genetic and epigenetic changes within the regulatory regions controlling CNR1 expression contribute to these differences, we isolated the human CNR1 promotor (CNR1prom) and demonstrate its activity in primary cells and transgenic mice. We also provide evidence of CNR1prom in CB 1 autoregulation and its repression by DNA-methylation. We further characterised a conserved regulatory sequence (ECR1) in CNR1 intron 2 that contained a polymorphism in linkage disequilibrium with disease associated SNPs. Deletion of ECR1 from mice using CRISPR genome editing significantly reduced CNR1 expression in the hippocampus. These mice also displayed reduced ethanol intake and hypothermia response to CB 1 agonism. Moreover, human specific Callele variants of ECR1 (ECR1(C)) drove higher levels of CNR1prom activity in hippocampal cells than did the ancestral T-allele. We further demonstrate a role for the AP-1 transcription factor in driving higher ECR1(C) activity. In the context of the known roles of CB 1 the current study suggests a mechanism through which ECR1(C) may be neuroprotective in the hippocampus against stress.
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The cell-specific approaches used in our study to determine the functional effects of genetic and epigenetic changes on the activity of tissue-specific regulatory elements at the CNR1 locus represent an important step in gaining a mechanistic understanding of cannabinoid pharmacogenetics.
Introduction
The cannabinoid-1 receptor (CB 1 ) is expressed in areas of the nervous system that include the hypothalamus and the hippocampus where CB 1 plays a critical role in appetite regulation (1) and neuroprotection against stress (2). For this reason, CB 1 has been explored as a target for drugs to treat diseases including obesity and depression (1, 3). There are numerous examples of the successful use of cannabinoid drugs in the treatment of disease. For example, Sativex (a combination drug comprising of plant cannabinoids, delta-9-tetrahydrocannabidiol (THC) and cannabidiol (CBD)) supresses the chronic pain and spasticity associated with multiple sclerosis (4, 5). However, the synthetic CB 1 antagonist rimonabant, marketed as an appetite suppressor, was withdrawn because 26% of patients reported depression, anxiety and feeling of suicidality (6).
Moreover, there is strong evidence of a genetic component to the psychotic, cognitive and addictive side effects of CB 1 agonists (7, 8) . Given the potential benefits of the pharmacological manipulation of CB1 it is essential to gain a better understanding of cannabinoid pharmacogenetics to facilitate the development and application of safe and effective cannabinoid-based therapeutics.
The current study examines the hypothesis that polymorphic and epigenetic changes in the regulatory regions that ensure the correct tissue specific expression of the CNR1 gene (encodes the CB 1 receptor), alter the regulation of CNR1 which may contribute to differences in response to drugs that target the CB 1 receptor. Using a unique combination of comparative genomics, reporter assays in primary and transformed cell cultures, chromatin immunoprecipitation, in-vivo CRISPR/cas9 gene editing in mice, in-vivo gene expression and phenotype analysis we have dissected and characterised some of the components of the regulatory mechanisms that modulate the tissue specific expression of the human CNR1 gene. The current study also highlights the role of regulatory polymorphisms in the differential activation of these regulatory components by CB 1 agonists and identifies a role for DNA methylation in controlling CNR1 gene expression. We will discuss these novel observations within the context of cannabinoid pharmacogenomics.
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Primary Cell culture. 1-day old male and female Sprague-Dawley neonate rats were euthanized in accordance with current UK Home Office schedule 1 guidelines. Hippocampal or hypothalamic tissues were dissected into ice cold Neurobasal-A medium (Life Technologies). Cells were dissociated using a combination of trypsin and papain solution followed by gentle agitation from pooled tissues to reduce variability and cultured in poly-d-lysine coated 24-well plates as previously described (11) at a density of 180,000 cells per well as assessed using a Biorad TC10 cell viability counter. Cells were maintained at 37°C in 5% CO 2 for up to 7 days in vitro in Neurobasal-A medium supplemented with 2% B27, 2mM L-glutamine, 50 μ g/ml Streptomycin and 50U Penicillin (Life Technologies) with the medium changed on the first day after plating and then every 3 days. Cultures were transfected 4 days after plating with luciferase plasmids ( together with pcDNA-FLAG-FosWT (Addgene 8966) or empty expression vector (pcDNA3.1, Thermofisher; V79020) plasmid using jetPRIME as per manufacturer's instruction (Polyplus IllkirchFrance).
Luciferase reporter assays. 
Generation of gRNA molecules by a novel annealed oligo template (AOT) method.
Single guide RNA (sgRNA) molecules were designed to disrupt the mouse ECR1 enhancer (mECR1; Fig. 1 ) using the optimised CRISPR design tool (http://CRISPR.mit.edu/). To remove the need for cloning of the guide RNA template into a plasmid as previously described (13) Jolla, CA, USA).
Results

CNR1prom supports reporter gene expression in hippocampus and hypothalamic cells.
Luciferase reporter studies involving magnetofection of reporters into primary cells demonstrate that the CNR1 promoter(9) (CNR1prom; Fig 1A) is significantly more active in primary hypothalamic and hippocampal cell cultures than the empty luciferase vector. Further analysis of the CNR1prom using a LacZ reporter (pCNR1prom-LacZ; Figure 2A ) in 2 separate transgenic mouse lines showed that LacZ gene expression ( Fig 2D) did not reflect the expression of the endogenous CNR1 gene in the hippocampus (Fig2 E). However, in both pCNR1prom-LacZ transgenic lines, significant evidence of CNR1 promoter activity was found in the hypothalamus and amygdala that reflected expression of the endogenous gene (Fig 2F and G) . QrtPCR to show a significant (15-30%) increase in CNR1 mRNA expression ( figure 2H ).
Furthermore, transfection of CNR1prom-Luc into primary hippocampal cells, and treatment with Win55,212-2 increased the activity of CNR1prom-luc suggesting a role for CNR1prom in CB 1 autoregulation ( Fig 2I) .
CNR1prom is strongly repressed by CpG-methylation in hippocampal cells. To determine the effects of CpG methylation on CNR1 activity we first cloned CNR1prom into a CpGfree luciferase vector that lacks any CpG dinucleotides and exposed these plasmids to the enzyme M.SssI; that specifically methylates at CpG dinucleotides, for varying levels of time up to one hour and transfected these plasmids into primary hippocampal cells. We observed that CpG-methylation strongly repressed CNR1prom activity suggesting that CNR1prom is very susceptible to this environmentally modulated process in hippocampal cells (Fig 2J) . (24) and alcohol abuse (25, 26) . Because this LD block was non-coding we used comparative genomics to identify functional sequences based on the hypothesis that high (sequence-sequence) and deep (conservation through evolution) conservation reflects functionality (27, 28). We identified a sequence that demonstrated high levels of conservation in all higher vertebrates ( Fig 1A and B ) and which contained a SNP (rs9444584) in high LD with both rs2023239 and rs9450898 ( Fig 1B) (11). To determine the possible function of this sequence we used CRISPR genome editing to disrupt the most highly conserved core region of ECR1 from the mouse genome ( Fig 3A) by microinjecting single guide RNA (gRNA; gRNAECR1a and gRNAECR1b; Fig 3A) molecules, designed to disrupt the core region of ECR1, centred on a sequence homologous to that containing the human rs9444584 polymorphism (Fig 3A) , together with CAS9 mRNA into the cytoplasm of fertilised single cell mouse embryos. We derived 3 lines containing a deletion that closely matched the PAM sequence of our guides and were unable to detect off target effects (29). These deletions were associated with a 17% reduction in CNR1 mRNA in the hippocampus of these lines ( Fig 3B) . Although there was some evidence of reduced expression in the hypothalamus it failed to reach significance ( Fig 3C) . These observations suggest
a role for ECR1 as a tissue specific regulatory sequence with greater relevance for CNR1 expression in the hippocampus.
Disruption of ECR1 reduces the CB 1 activated hypothermia response and reduces ethanol intake. To determine the effects of ECR1 disruption on CB 1 response we injected adult male and female ECR1KO and wild-type mice with Win55,212-2 (5mg/kg; i.p) and observed that, 30 minutes after injection, ECR1KO mice displayed a significantly reduced hypothermia response compared to wild types (WT) consistent with a reduction in CB 1 receptor expression ( Fig 3D) .
Because mice lacking CB 1 also have reduced ethanol intake (15) and the haplotype block harbouring the rs9444584 polymorphism is associated with increased susceptibility to alcohol abuse (26) we explored the effects of the ECR1 knockout on the ethanol intake of ECR1KO mice in comparison to wild type littermates. We observed that, despite having the same total fluid intake ( Fig 3E) , ECR1KO mice drank significantly less 10% ethanol than WT animals (Fig3F and G).
Allelic variants of the human ECR1 enhancer differentially regulate the activity of
CNR1prom. To explore the tissue specificity of interaction of ECR1 with CNR1prom (30) we cloned allelic variants of ECR1 into the CNR1prom-luc reporter construct (Fig 2A) and magnetofected these constructs into rat hippocampal and hypothalamic primary cell cultures. We found that, although the C-allele did not increase CNR1prom activity in hypothalamus, we observed strong enhancement of CNR1prom activity in hippocampal cells ( Fig 4A) demonstrating evidence of enhancer-promoter specificity in these cells. However, the T-allele failed to enhance activity of CNR1prom in hippocampal neurones and repressed its activity in hypothalamus ( Fig 4A) .
The ECR1C allele supports the auto-regulatory properties of CNR1prom. Reporter constructs containing allelic variants of the ECR1 enhancer and CNR1prom were magnetofected into hippocampal primary cell cultures which were then treated with Win55,212-2 (100nM). Dual luciferase analysis of these cells demonstrated that incubation of cells with Win55,212-2 significantly increased luciferase expression in the presence of the ECR1(C) allele ( Fig 4B) .
However, we observed a significant reduction in the response of CNR1prom to Win55,212-2
treatment in the presence of ECR1(T) suggesting that ECR1T does not support autoregulation of
CNR1prom in hippocampal cells (Fig4B).
ECR1C interacts with higher affinity to AP-1 transcription factor than ECR1T.
Bioinformatic analysis (RegSNP) of the ECR1 locus predicts that the AP-1 transcription factor (a dimer of cFOS and cJUN) binds to ECR1(C) with high affinity but with reduced affinity to ECR1(T).
This is an interesting prediction as cFOS and CNR1 are co-expressed in the hippocampus (Fig 5A   and B) and several studies have demonstrated that an upregulation of CB1 activity also increases activation of cFOS (31, 32). To explore this prediction, we magnetofected either the ECR1CLuc or ECR1TLuc plasmids (Fig 2A) into primary rat hippocampal cell cultures. After 48 hours chromatin was extracted and fragmented using restriction digestion or sonication (Fig5C and supplementary data). Quantitative PCR of extracted chromatin against the luciferase gene indicated equal transfection efficiencies and were used to normalise transfection. This chromatin was then incubated with antisera against the AP-1 or CTCF proteins. After recovery of specific antibodyprotein-DNA complexes QPCR specific for human ECR1 was used to determine comparative levels of human ECR1 DNA immunoprecipitation. Despite using two different genome fragmentation techniques we consistently observed a higher signal from primary cells transfected with ECR1CLuc compared to those transfected with ECR1TLuc suggesting an increased affinity for AP-1 to the Callele ( Fig 5C and supplementary data) . Intriguingly, we also observed increased binding of CTCF to the T-allele of ECR1 (Supplementary data).
To determine whether the increased binding affinity of AP-1 to ECR1(C) was reflected in enhancer activity we carried out co-transfection analysis in a human neuroblastoma cell line with luciferase reporters containing the C-allele and T-allele of ECR1 in combination with an expression vector expressing the cFOS protein (pcDNA--FosWT). We observed that co-expression of cFOS with a luciferase reporter containing a promoter known to respond strongly to AP-1 (pAP1-3) was highly up-regulated ( Figure 5D ). We also observed a significant increase in expression of luciferase in cells co-transfected with ECR1CLuc and pcDNA-cFOS. Consistent with our previous primary cell
transfection and ChIP data we found no significant upregulation in activity of ECR1(T) in the presence of cFOS expression (Fig5D).
Discussion
Although targeting the CB1 receptor has clear therapeutic potential the beneficial effects of cannabinoid drug treatments are not universal (7). Thus, understanding the pharmacogenetics of the CNR1 locus within the human population will be essential to the therapeutic development of the cannabinoids. Because there is evidence that the majority of functional genomic variations occurs outside of coding regions (33) and the CNR1 coding region does not contain polymorphisms that occur in greater than 1% of the population, the current study sought to better understand the noncoding genetic and epigenetic influences controlling the tissue specific expression of the CNR1 gene as possible contributory factors in the pharmacogenomics of cannabinoid response.
We first identified that CNR1prom (9) was active in different primary cell types as well as in specific regions of the brain in transgenic mice expressing a LacZ reporter construct driven by the human CNR1 promoter. In addition, our primary hippocampal cell-based studies support previous observations in T-cells and liver (16, 17) that CNR1 is under autocrine control and we demonstrate that the CNR1 promoter is involved. Moreover, given the known role of CpG-methylation in modulating CNR1 expression (34, 35) our observed sensitivity of CNR1prom to methylation may have important ramifications for understanding the mechanistic effects of environmental factors, such as early life stress, disease or deprivation, on cannabinoid response.
Disrupting the ECR1 enhancer element using CRISPR genome editing demonstrated that ECR1 is important for maintaining normal levels of CNR1 expression within the hippocampus. This experiment also permitted in-vivo behavioural studies to determine the effects of ECR1 disruption on core body temperature, following CB1 activation, and ethanol intake. This last observation is interesting as human ECR1 contains the rs9444584 polymorphism; part of a haplotype block that has been implicated in reduced CNR1 expression (9) and increasing susceptibility to alcohol abuse (26). Thus, in addition to its possible role in stratification of drug response, further functional analysis of this polymorphism in vivo and in the clinic may reveal important insights into the causes of alcohol abuse.
From the perspective of tissue specific regulation our observations suggest that ECR1 may play a more substantive role in supporting expression of CNR1 in the hippocampus than the hypothalamus implying that SNPs within ECR1 would have a greater effect in the hippocampus. As we have shown that the C-allele of ECR1 is more active in hippocampal cells, these observations suggest that the human specific C-allele of ECR1 may drive higher expression of CNR1 in hippocampus consistent with previous observations (9). Considering the known neuroprotective role of CB 1 activation against the effects of stress in the hippocampus (36) it has not escaped our attention that the C-allele may play a role in protecting the hippocampus against the depressive and anxiety inducing effects of stress. In this context, and from the perspective of adaptive evolution, it is interesting that the C-allele has undergone positive selection in European and Asian populations where its frequency exceeds 80% compared to the ancestral T-allele. Although bottleneck effects might account for this difference, we cannot rule out the possibility that selection for an allele which drives higher levels of CB1 receptor in the hippocampus may have been beneficial to early human populations by resisting the anxiety and depressive effects of stress.
These observed differences in the activity of the C and T-alleles of ECR1 in the hippocampus may also influence the observed effects of CB 1 targeted therapeutics such as the anti-obesity drug rimonabant in humans. Rimonabant's main mode of action is through antagonism/inverse agonism of the CB 1 receptor in the hypothalamus, which leads to a reduction in appetite. Rimonabant was withdrawn from the market as it was linked to an increase in depressed and suicidal feelings in 26% of patients (6). If we consider what is known about the neuroprotective role of CB 1 against stress in the hippocampus, the increase in anxiety and depression in these individuals is not surprising as the appetite reducing antagonism of CB 1 in the hypothalamus would be accompanied by antagonism of CB 1 in the hippocampus. Indeed, reports of increased anxiety (37) and depression-like (38) behaviours have been reported in rodents, who harbour the ancestoral T-allele of ECR1, following chronic administration of rimonabant. What is probably more noteworthy is the observation that 74% of patients did not experience anxiety/depression like symptoms and responded positively to rimonabant. Based on our observations, we propose that the human specific C-allele of ECR1 may 1 5 | P a g e induce higher levels of CB1 expression in the hippocampus in humans, thus protecting individuals from the anxiolytic and depression forming effects of stress following treatment with rimonabant (2).
Our analysis goes on to identify a possible molecular mechanism that may explain differences in the activity of the C and T-alleles of ECR1 based on variable affinity to the AP-1 transcription factor which is known to be expressed in the hippocampus. Using a unique experiment based on ChIP analyses of magnetofected primary hippocampal cells we demonstrated increased affinity for AP-1 to the C-allele of ECR1(C). To verify this observation, we also showed that expression of cFOS; one of the proteins that forms the AP-1 complex, activates the ECR1(C) enhancer but not ECR1(T) in co-transfected cells. This observation was interesting as several studies have demonstrates that stimulation of CB 1 induces binding of AP-1 to DNA and expression of cFOS (31, 32) . This was particularly evident in the hippocampus where CB1 and cFOS are co-expressed in the CA1, CA3
and dentate gyrus (39). Further bioinformatics analysis predicted binding of the CTCF transcription factor; a known marker of insulator function, with higher affinity to the T-allele, a prediction that we also support using ChIP assays. These observations raise an interesting possibility that the ancestral T-allele of ECR1 would act as a weak enhancer with insulator properties in the hippocampus of most vertebrates. However, the change to the C-allele in humans, that increased binding affinity of AP-1 and increased the enhancer like properties of ECR1 in specific tissues, may have proved advantageous to specific populations faced with new and stressful circumstances thus expanding the frequency of the C-allele in these populations.
Taken together, the evidence discussed above suggests a role for methylation of CNR1prom and allelic variation within ECR1 in modulating the expression of CNR1. Although much remains to be done to conclusively establish a role for these observations in alcohol abuse and drug effects in humans, our unique primary cell-based and in-vivo studies lay the foundation for future studies of the contribution of these genetic and epigenetic factors in the pharmacogenetics of the cannabinoids and the possible effects on human health and disease susceptibility. We believe that the current manuscript not only provides a platform for the further study of the effects of polymorphisms and DNA-methylation on the pharmacogenomics of the cannabinoids but also 1 6 | P a g e provides a functional blueprint for understanding the role of the non-coding genome in health and disease.
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